This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Monitoring for safety

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Sulphasalazine is potentially toxic and so must be carefully monitored (1,2).

FBC, LFTs

  • every 1-2 weeks for 2 months; then 3-monthly for a year; then 6-monthly

Watch for trends as well as absolute levels of:

  • Hb & MCV
  • differential WCC
  • platelets

Any patient receiving sulphasalazine should be advised about the need to have a full blood count immediately if they develop unexplained purpura, bleeding, bruising, sore throat, fever or excessive tiredness (1).

FBC, LFTs Every 1-2 weeks for 2 months; then 3-monthly for a year; then 6-monthly

Ideally results should be recorded in a patient-held booklet.

Reference:

  1. Drug and Therapeutics Bulletin (2002), 39 (12), 91-95.
  2. MeReC Bulletin 2007;17(5):1-8.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page